For many years, the pulmonology field has been dominated by large population conditions, such as asthma & COPD. That is changing. There is now a deeper understanding and renewed interest in rare diseases such as Idiopathic Pulmonary Fibrosis, Pulmonary Arterial Hypertension, and Chronic Thromboembolic Pulmonary Hypertension. Biopharma`s challenge is to develop innovative therapies and build successful launch strategies so that they can meet the complex needs of both patients and their treating physicians. SGI has a specific focus on these rare pulmonary diseases, providing insight from both the physician and the patient perspective.

Direct from our Research!

A large scale chart audit of over 800 patients with IPF provided some frightening insight:  Despite being a fatal disease, only about 40% of diagnosed patients were currently on treatment with one of the FDA approved therapies, Roche’s Esbriet or Boehringer Ingelheim’s Ofev.  You can find out why in our RealWorld Dynamix: IPF report which comes with a PowerPoint format with access to the de-identified patient record database for subsequent analysis.

Reports new KS-02

In-depth analysis of a robust sample of patient journeys detailing the realities of current practice.

RealWorld Dynamix: Idiopathic Pulmonary Fibrosis US 2016